« Return to News | Clinical Intelligence

Plexxikon initiates phase II trial

Wednesday, March 9, 2011 10:50 AM

Plexxikon has treated its first patient in a phase II trial in Hodgkin lymphoma with PLX3397. This agent is an oral, selective inhibitor that down-modulates two key cell types thought to mediate the progression of Hodgkin lymphoma tumors: macrophages and mast cells.

The trial is a multi-center, single-arm trial with approximately 30 patients enrolled who have been diagnosed with Hodgkin lymphoma who have relapsed or become refractory to standard therapies. Objectives of the trial include assessing the efficacy of orally administered PLX3397 as measured by overall response rate, as well as the duration of response, the disease control rate, progression-free survival, response biomarkers and overall safety.

"PLX3397 is an important product candidate both for Plexxikon's growing oncology franchise and for our FMS portfolio," said K. Peter Hirth, Ph.D., chief executive officer of Plexxikon. “Since PLX3397 targets multiple facets of Hodgkin lymphoma pathology, we expect treatment benefits to include both tumor growth inhibition, and reduction of invasiveness and metastatic spread.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.